Assmann Jorn L J C, van Gammeren Adriaan J, Sprenger Reinier A, de Wit Saskia, Ceelie Huib, Leebeek Frank W G, Schellings Mark W M
Department of Clinical Chemistry, MaasstadLab, Maasstad Hospital, Rotterdam, the Netherlands.
Department of Clinical Chemistry and Hematology, Amphia Hospital, Breda, the Netherlands.
Res Pract Thromb Haemost. 2024 Nov 29;9(1):102638. doi: 10.1016/j.rpth.2024.102638. eCollection 2025 Jan.
Pulmonary embolism (PE) is a life-threatening condition with high morbidity and mortality. The diagnosis of PE is challenging due to nonspecific symptoms, making reliable diagnostic tools essential. This study addresses the clinical impact of interassay variability in D-dimer measurements on the utilization and diagnostic yield of computed tomography pulmonary angiography (CTPA).
To investigate the effect of different D-dimer assays on the decision to perform CTPA and the subsequent diagnostic yield in patients with suspected PE.
This retrospective, multicenter cohort study analyzed data from 3 teaching hospitals in the southwest region of the Netherlands, covering the years 2018, 2019, 2022, and 2023. The study included data from 40,096 clinically requested D-dimer results and 11,372 CTPA records of patients with suspected PE. The D-dimer assays used were the Roche Tina-quant and Siemens INNOVANCE.
The study found significant differences in CTPA utilization and diagnostic yield based on the D-dimer assay used. In 2018 to 2019, hospitals using the Roche Tina-quant assay ordered 21% fewer CTPA scans and had a 9% higher positivity rate compared with those using the Siemens INNOVANCE assay.
The findings highlight the necessity for assay-specific cutoff values or, ideally, the standardization of the D-dimer assay to optimize the accuracy and efficiency of PE diagnosis. This study demonstrates that the choice of D-dimer assay significantly influences the clinical management of suspected PE, affecting both the number of CTPA scans performed and the positivity rate of these scans. Implementing assay-specific cutoff values or standardization of the D-dimer assay could reduce unnecessary CTPA scans, minimize patient exposure to radiation, and lower healthcare costs. These results advocate enhanced collaboration between clinicians and laboratory specialists to accurately interpret D-dimer results within the context of the specific assay used. Future research should validate these findings in prospective studies and explore standardized protocols that account for interassay variability.
肺栓塞(PE)是一种危及生命的疾病,发病率和死亡率都很高。由于症状不具特异性,PE的诊断具有挑战性,因此可靠的诊断工具至关重要。本研究探讨了D-二聚体检测中不同检测方法之间的差异对计算机断层扫描肺动脉造影(CTPA)的应用及诊断率的临床影响。
研究不同D-二聚体检测方法对疑似PE患者进行CTPA检查决策及后续诊断率的影响。
这项回顾性多中心队列研究分析了荷兰西南部3家教学医院2018年、2019年、2022年和2023年的数据。该研究纳入了40096例临床要求的D-二聚体检测结果数据以及11372例疑似PE患者的CTPA记录。所使用的D-二聚体检测方法为罗氏Tina-quant和西门子INNOVANCE。
研究发现,根据所使用的D-二聚体检测方法,CTPA的应用及诊断率存在显著差异。在2018年至2019年期间,与使用西门子INNOVANCE检测方法的医院相比,使用罗氏Tina-quant检测方法的医院所开具的CTPA扫描检查少21%,阳性率高9%。
研究结果凸显了针对特定检测方法设定临界值的必要性,或者理想情况下,对D-二聚体检测进行标准化,以优化PE诊断的准确性和效率。本研究表明,D-二聚体检测方法的选择显著影响疑似PE的临床管理,影响CTPA扫描的执行数量以及这些扫描的阳性率。实施针对特定检测方法的临界值或对D-二聚体检测进行标准化可以减少不必要的CTPA扫描,使患者减少辐射暴露,并降低医疗成本。这些结果提倡临床医生和实验室专家加强合作,以便在使用特定检测方法的背景下准确解读D-二聚体检测结果。未来的研究应在前瞻性研究中验证这些发现,并探索考虑到不同检测方法之间差异的标准化方案。